SYK Stryker Corporation
USHealthcareAs of 2026-08-24
Why SYK matters now
Stryker Corporation (SYK) is a US stock in Healthcare. The latest InvestLog snapshot shows $327.85 with -0.49% on the session and $125.68B in market capitalization; recent performance reads 1-month -3.13% and YTD -12.43%.
The latest financial table shown here is Q1 2026, with revenue of $6.02B, net income of $745.0M, and EPS of $1.93. Investors can compare that operating picture with valuation signals such as P/E 39.15 and FCF yield 3.9%.
InvestLog's latest related AI research is a Insider Sale note titled "Stryker Ronda E sells $117.8M of SYK". The latest indexable market news headline is "Ally Financial Inc. Invests $4.09 Million in Stryker Corporation SYK" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $394.00; recent insider activity includes Stiles Spencer S filing G-Gift; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
39.15
PEG
4.63
P/B
5.13
P/S
4.67
EV/EBITDA
21.15
DCF Value
$334.96
FCF Yield
3.9%
Div Yield
1.1%
Margins & Returns
Gross Margin
63.7%
Operating Margin
21.3%
Net Margin
13.2%
ROE
15.1%
ROA
7.2%
ROIC
9.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.02B | $745.0M | $1.93 |
| Q4 2025 | $7.17B | $849.0M | $2.20 |
| FY 2025 | $25.12B | $3.25B | $8.40 |
| Q3 2025 | $6.06B | $859.0M | $2.22 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$387.46
Target (Median)
$394.00
Target Range
$315.00 - $465.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Stryker Ronda E sells $117.8M of SYKStryker Ronda E 内部减持 史赛克公司 (SYK) $117.8M
On August 19, 2026, Stryker Corporation (ticker: SYK) director RONDA E STRYKER sold 350,000 shares of common stock in an open-market transaction at $336.2026年8月19日,史赛克公司(股票代码SYK)董事RONDA E STRYKER以每股336.50美元的价格在场内出售350,000股公司普通股,交易总金额达117,776,128美元。该笔交易于次日(2026年8月20日)通过美国SEC的Form 4文件公开披露,此次出售占史赛克当前1256亿美元总市值的0.094%。
SYK earnings call: guidance, demand, margins, analyst Q&A史赛克公司 (SYK) 电话会要点:指引、需求、利润率、分析师问答
Preston Wells: For 2026, we continue to expect our full year effective tax rate to be in the range of 15% to 16%.普雷斯顿·威尔斯:我们仍预计2026年全年有效税率处于15%至16%的区间内。
SYK earnings release — EPS beat +5.7% · revenue in line +0.1%史赛克公司 (SYK) 财报发布 — EPS 高于预期+5.7% · 营收 基本符合预期+0.1%
Stryker Corporation reported EPS $3.69 vs $3.49 estimate and revenue $6.6B vs $6.6B estimate.史赛克公司 公布财报:EPS $3.69 vs $3.49 预期,营收 $6.6B vs $6.6B 预期。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.79
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.